Filing Flows › Industrials › Neogenomics (NEO)
Neogenomics (NEO) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 28, 2026 · Neogenomics (NEO) Q3 2026 earnings results →
Q3 2026 Revenue up 11% year over year to $209M · 4¢ of every $1 of revenue lost · operating margin -3.8%
Neogenomics made $209M in Q3 2026 (+11% Y/Y): Client direct billing $136M, Commercial insurance $44.7M, Medicare and other government $29.0M. Operating margin -3.8%, net loss $7.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 28, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $209.3M in Q3 2026, up 11% year over year and up 4% from the previous quarter. Client direct billing was the largest line at 65% of revenue. Commercial insurance added $12.2M year over year (up 38%), 57% of the total change.
Gross margin was 46.2%, up 3.3 points from Q3 2025. Operating costs exceeded revenue by $7.9M, an operating margin of -3.8%. Operating expenses fell 3% while revenue rose 11%. The fastest-growing cost line was Sales & marketing (+27%). The quarter ended with a net loss of $7.5M, after a profit of $2.2M the previous quarter.
Operating cash flow was −$8.9M. Non-cash charges added back $16.2M of depreciation and amortization and $8.8M of share-based compensation. Working capital and other items used $26.4M. Capital expenditures of $11.8M exceeded it, leaving free cash flow of −$20.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 28, 2026 | $209M | +11% | -3.8% | −$7.5M | −$8.9M |
| Q2 2026 | 10-Q | Jul 28, 2026 | $202M | +11% | -4.8% | $2.2M | $20.0M |
| Q1 2026 | 10-Q | Apr 28, 2026 | $187M | +11% | -9.8% | −$17.1M | −$8.1M |
| Q4 2025 | 10-K | Feb 17, 2026 | $190M | +11% | -7.1% | −$9.9M | $1.3M |
| Q3 2025 | 10-Q | Oct 28, 2025 | $188M | +12% | -14.4% | −$27.1M | $8.9M |
| Q2 2025 | 10-Q | Jul 29, 2025 | $181M | +10% | -26.3% | −$45.1M | $20.3M |
| Q1 2025 | 10-Q | Apr 29, 2025 | $168M | +8% | -16.6% | −$25.9M | −$25.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- Medicare & Medicaid — 13% of its revenue · Stated in 10-K (sentence) · source
About Neogenomics
NeoGenomics, Inc., a Nevada corporation (referred to individually as the “Company” or collectively with its subsidiaries as “NeoGenomics,” “we,” “us,” or “our” in this Annual Report on Form 10-K) is the registrant for SEC reporting purposes. Our common stock is listed on The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “NEO.” NeoGenomics provides a wide range of oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts who specialize in pathology and oncology. We operate a network of cancer-focused testing laboratories in the United States and the United Kingdom. Our mission is to save lives by improving patient care.
In its own words, from its 10-K, filed Feb 17, 2026.
Neogenomics against its Services-Testing Laboratories peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +11% against the peers' median +11%. Operating margin: -3.8% against the peers' median -3.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NEO Neogenomics | Q3 2026 | $209M | +11% | -3.8% |
| ULS UL Solutions | Q3 2026 | $823M | +5% | 19.7% |
| AIDX 20/20 Biolabs | Q2 2026 | $731K | +36% | -170.3% |
Source: Neogenomics 10-Q on SEC EDGAR · CIK 1077183 · Services-Testing Laboratories
13F: who owns NEO and who is buying
More on NEO
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results